AMRX

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: JNJ PFE NVS TAK TEVA PRGO FMS RDY SNN

| Held by: IJR VTI VB IWM VBR VXF SPSM IWO DFAS IJT

Scroll to Statements

Index	RUT	P/E	53.43	EPS (ttm)	0.22	Insider Own	50.13%	Shs Outstand	314.56M	Perf Week	-10.65%
Market Cap	3.72B	Forward P/E	10.13	EPS next Y	1.17	Insider Trans	-0.12%	Shs Float	156.91M	Perf Month	-19.52%
Enterprise Value	6.18B	PEG	0.59	EPS next Q	0.17	Inst Own	45.68%	Short Float	6.32%	Perf Quarter	-3.11%
Income	72.06M	P/S	1.23	EPS this Y	16.22%	Inst Trans	2.05%	Short Ratio	3.86	Perf Half Y	17.24%
Sales	3.02B	P/B	-	EPS next Y	21.03%	ROA	2.01%	Short Interest	9.92M	Perf YTD	-6.11%
Book/sh	-0.23	P/C	11.97	EPS next 5Y	17.31%	ROE	-	52W High	15.42 -23.28%	Perf Year	34.58%
Cash/sh	0.99	P/FCF	15.43	EPS past 3/5Y	- -18.36%	ROIC	2.77%	52W Low	6.68 76.96%	Perf 3Y	704.76%
Dividend Est.	-	EV/EBITDA	9.92	Sales past 3/5Y	10.92% 8.66%	Gross Margin	36.88%	Volatility	4.52% 3.41%	Perf 5Y	96.51%
Dividend TTM	-	EV/Sales	2.05	EPS Y/Y TTM	160.50%	Oper. Margin	13.21%	ATR (14)	0.51	Perf 10Y	-67.43%
Dividend Ex-Date	-	Quick Ratio	1.48	Sales Y/Y TTM	8.05%	Profit Margin	2.39%	RSI (14)	21.66	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	2.17	EPS Q/Q	206.58%	SMA20	-14.29%	Beta	1.33	Target Price	16.80
Payout	0.00%	Debt/Eq	-	Sales Q/Q	11.47%	SMA50	-13.79%	Rel Volume	1.12	Prev Close	12.11
Employees	8500	LT Debt/Eq	-	Earnings	Feb 27 BMO	SMA200	9.63%	Avg Volume	2.57M	Price	11.83
IPO	Dec 19, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.07% 0.86%	Trades		Volume	2,888,564	Change	-2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$15
Jun-06-25	Initiated	Goldman	Buy	$12
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight	$9 → $12
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral	$9
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform	$5
Mar-08-21	Upgrade	Goldman	Sell → Buy	$4 → $6.50
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy	$5.50
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight	$4.50 → $6
Jul-27-20	Initiated	Goldman	Sell	$4
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$11 → $5
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11 → $6
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight	$9
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy	$13
Mar-20-19	Initiated	SunTrust	Buy	$16
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$16 → $12

Show Previous Ratings

Mar-10-26 12:02AM	3 Reasons to Avoid AMRX and 1 Stock to Buy Instead (StockStory)
Mar-09-26 08:22AM	New Strong Buy Stocks for March 9th (Zacks)
07:11AM	Best Value Stocks to Buy for March 9th (Zacks)
Mar-05-26 04:05PM	Amneal to Participate in Upcoming Investor Conference (GlobeNewswire)
Feb-27-26 04:04PM	Amneal Pharmaceuticals Inc (AMRX) Q4 2025 Earnings Call Highlights: Strong Financial Growth and ... (GuruFocus.com)
03:21PM	Loading…
03:21PM	Why Amneal (AMRX) Stock Is Trading Lower Today (StockStory)
10:24AM	Amneal Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
09:17AM	Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million (Benzinga)
07:15AM	Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates (Zacks)
06:39AM	Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations (StockStory)
06:00AM	Amneal Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-25-26 10:03PM	Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow (StockStory)
Feb-23-26 09:40AM	Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now? (Zacks)
09:06AM	Viatris Stock to Report Q4 Earnings: What's in the Cards? (Zacks)
09:53AM	Loading…
Feb-19-26 09:53AM	Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-18-26 04:05AM	Amneal Pharmaceuticals, Inc. (AMRX) Added to S&P SmallCap 600 Index, Boosting Investor Visibility (Insider Monkey)
Feb-13-26 11:26AM	Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market (PR Newswire)
Feb-12-26 11:31PM	3 Russell 2000 Stocks We Find Risky (StockStory)
Feb-09-26 09:40AM	Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-06-26 01:58PM	Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y (Zacks)
Feb-05-26 09:40AM	Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now? (Zacks)
Feb-04-26 11:32PM	3 Small-Cap Stocks That Fall Short (StockStory)
Feb-03-26 11:23AM	IQVIA Set to Report Q4 Earnings: Here's What You Should Know (Zacks)
Jan-28-26 04:05PM	Amneal Pharmaceuticals Added to S&P SmallCap 600 Index (GlobeNewswire)
12:10PM	Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:11AM	Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? (Zacks)
Jan-27-26 06:02PM	TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 (PR Newswire)
12:59PM	HCA Healthcare Q4 Earnings Beat Estimates on Strong Patient Volumes (Zacks)
08:00AM	Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 (GlobeNewswire)
11:02PM	Loading…
Jan-25-26 11:02PM	2 Reasons to Sell AMRX and 1 Stock to Buy Instead (StockStory)
Jan-22-26 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-15-26 09:40AM	Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? (Zacks)
Jan-13-26 09:04PM	Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025 (MarketBeat)
Jan-10-26 02:57PM	Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14 (Insider Monkey)
Jan-07-26 02:55PM	Can This Healthcare Stock Keep Going After a Nearly 70% Surge? (Barchart)
Jan-06-26 11:44AM	ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? (Zacks)
Dec-22-25 04:01PM	Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA (GlobeNewswire)
04:00PM	mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA (PR Newswire)
Dec-09-25 04:01PM	Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals (GlobeNewswire)
Dec-05-25 08:00AM	Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinson's Disease (GlobeNewswire)
Dec-02-25 08:00AM	Amneal to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol (GlobeNewswire)
Dec-01-25 04:01PM	Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% (GlobeNewswire)
Nov-28-25 10:56AM	ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? (Zacks)
Nov-21-25 08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 10:33PM	Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks (StockStory)
Nov-14-25 08:44AM	ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? (Zacks)
05:10AM	Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat (Insider Monkey)
Nov-13-25 04:01PM	Amneal Receives U.S. FDA Approval for Iohexol Injection (GlobeNewswire)
Nov-11-25 11:35PM	3 Stocks Under $50 We Steer Clear Of (StockStory)
Nov-04-25 09:33AM	Implied Volatility Surging for Amneal Pharmaceuticals Stock Options (Zacks)
Oct-31-25 01:00PM	Why Amneal (AMRX) Stock Is Up Today (StockStory) +8.20%
Oct-30-25 04:30PM	Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
09:30AM	Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:15AM	Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
06:47AM	Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars (StockStory)
06:14AM	Amneal: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Amneal Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-29-25 04:05PM	Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol (GlobeNewswire)
09:39AM	What To Expect From Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 11:17PM	Amneal Earnings: What To Look For From AMRX (StockStory)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-27-25 10:00AM	BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Amneal Launches Brekiya - the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches (GlobeNewswire)
Oct-23-25 10:00AM	Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-21-25 10:42PM	Amneal Pharmaceuticals, Inc. (AMRX): A Bull Case Theory (Insider Monkey)
Oct-07-25 09:40AM	Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? (Zacks)
Oct-06-25 08:07AM	Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus (Zacks)
08:00AM	Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR (omalizumab) (Business Wire)
Oct-03-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-02-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
08:18AM	3 Lesser-Known Healthcare Names With Major Upside in Store (MarketBeat)
Oct-01-25 01:44PM	Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR Biosimilar, Targets Multi-Billion-Dollar Market (Insider Monkey)
Sep-30-25 04:05PM	Amneal to Report Third Quarter 2025 Results on October 30, 2025 (GlobeNewswire)
Sep-26-25 08:00AM	Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR (omalizumab) (GlobeNewswire)
Sep-23-25 08:00AM	Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% (GlobeNewswire)
Sep-15-25 05:29AM	Amneal secures FDA approval for sodium oxybate solution (Pharmaceutical Technology)
Sep-11-25 02:16PM	Why Amneal (AMRX) Stock Is Up Today (StockStory)
08:00AM	Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution (GlobeNewswire)
Sep-04-25 04:01PM	Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension (GlobeNewswire)
Sep-01-25 09:55AM	Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a Bet (Zacks)
Aug-25-25 09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out? (Zacks)
Aug-14-25 09:55AM	Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High? (Zacks)
Aug-13-25 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
08:50AM	Here's Why Momentum in Amneal (AMRX) Should Keep going (Zacks)
12:09AM	AMRX Q2 Deep Dive: New Product Launches and Specialty Momentum Shape Guidance (StockStory)
Aug-12-25 11:52PM	5 Revealing Analyst Questions From Amneal's Q2 Earnings Call (StockStory)
Aug-05-25 09:30AM	Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:30AM	Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico (GlobeNewswire)
07:15AM	Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates (Zacks)
06:16AM	Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets (StockStory)
06:14AM	Amneal: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Amneal Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 02:07PM	Viatris Poised to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
09:51AM	Bio-Techne Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
09:35AM	Amneal Pharmaceuticals Inc (AMRX) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-03-25 11:08PM	Amneal Earnings: What To Look For From AMRX (StockStory)
Jul-31-25 02:44PM	Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT (Insider Monkey)

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nark Ted C	Director	Nov 17 '25	Sale	11.72	50,000	586,000	291,029	Nov 19 04:21 PM
Nark Ted C	Director	Nov 17 '25	Proposed Sale	11.82	50,000	591,250		Nov 17 03:06 PM
Shah Nikita	Executive Vice President	Nov 12 '25	Option Exercise	2.75	131,856	362,604	278,259	Nov 14 05:13 PM
Shah Nikita	Executive Vice President	Nov 12 '25	Sale	11.92	131,856	1,571,724	146,403	Nov 14 05:13 PM
NIKITA SHAH	OFFICER	Nov 12 '25	Proposed Sale	11.92	131,856	1,571,723		Nov 12 05:12 PM
Kiely John	Director	Aug 27 '25	Sale	9.23	32,000	295,360	225,433	Aug 28 04:25 PM
Kiely John	Director	Aug 27 '25	Proposed Sale	9.18	32,000	293,810		Aug 27 03:04 PM
Shah Nikita	Executive Vice President	Aug 22 '25	Sale	9.66	114,492	1,105,993	152,743	Aug 25 04:27 PM
Shah Nikita	Executive Vice President	Aug 25 '25	Sale	9.50	6,340	60,230	146,403	Aug 25 04:27 PM
BOYER ANDREW S	Executive Vice President	Aug 20 '25	Option Exercise	2.75	175,000	481,250	431,670	Aug 22 04:38 PM
BOYER ANDREW S	Executive Vice President	Aug 20 '25	Sale	9.38	279,244	2,619,309	152,426	Aug 22 04:38 PM
Shah Nikita	Officer	Aug 22 '25	Proposed Sale	9.70	36,796	356,921		Aug 22 04:03 PM
Shah Nikita	Officer	Aug 22 '25	Proposed Sale	9.74	84,036	818,931		Aug 22 12:18 PM
BOYER ANDREW S	Officer	Aug 20 '25	Proposed Sale	9.36	175,000	1,637,900		Aug 20 04:16 PM
BOYER ANDREW S	Officer	Aug 20 '25	Proposed Sale	9.30	104,244	969,469		Aug 20 10:26 AM
Shah Nikita	Executive Vice President	Aug 14 '25	Sale	9.29	71,694	666,037	267,235	Aug 15 04:31 PM
Konidaris Tasos	Executive Vice President & CFO	Aug 15 '25	Sale	9.43	219,159	2,066,669	122,152	Aug 15 04:30 PM
Konidaris Tasos	Executive Vice President & CFO	Aug 13 '25	Sale	9.22	161,365	1,487,785	460,517	Aug 15 04:30 PM
Konidaris Tasos	Executive Vice President & CFO	Aug 14 '25	Sale	9.30	119,206	1,108,616	341,311	Aug 15 04:30 PM
Konidaris Tasos	Officer	Aug 15 '25	Proposed Sale	9.39	219,159	2,057,903		Aug 15 11:14 AM
Shah Nikita	Officer	Aug 14 '25	Proposed Sale	9.25	71,694	663,065		Aug 14 04:10 PM
Shah Nikita	Executive Vice President	Aug 12 '25	Sale	9.04	50,000	452,000	338,929	Aug 13 04:40 PM
Daly Jason B.	EVP, Chief Legal Officer	Aug 12 '25	Sale	9.05	22,000	199,100	10,606	Aug 13 04:39 PM
BOYER ANDREW S	Executive Vice President	Aug 12 '25	Sale	9.05	33,436	302,596	256,670	Aug 13 04:38 PM
Konidaris Tasos	Officer	Aug 13 '25	Proposed Sale	9.27	169,206	1,568,539		Aug 13 03:08 PM
Konidaris Tasos	Officer	Aug 13 '25	Proposed Sale	9.02	111,635	1,006,947		Aug 13 10:41 AM
BOYER ANDREW S	Officer	Aug 12 '25	Proposed Sale	9.09	33,436	304,100		Aug 12 04:06 PM
Daly Jason B.	Officer	Aug 12 '25	Proposed Sale	9.00	22,000	198,000		Aug 12 04:04 PM
Shah Nikita	Officer	Aug 12 '25	Proposed Sale	9.06	50,000	453,000		Aug 12 03:09 PM
Patel Gautam	Director	Jun 16 '25	Sale	8.02	94,906	761,146	1,609,144	Jun 18 04:11 PM
Patel Gautam	Director	Jun 10 '25	Sale	8.02	56,426	452,537	1,704,050	Jun 12 04:19 PM
Shah Nikita	Executive Vice President	May 16 '25	Sale	7.58	49,140	372,481	388,929	May 19 04:16 PM
Shah Nikita	Officer	May 16 '25	Proposed Sale	7.50	49,140	368,550		May 16 04:02 PM
Kiely John	Director	May 12 '25	Sale	7.59	50,000	379,500	257,433	May 13 04:42 PM
Kiely John	Director	May 12 '25	Proposed Sale	7.57	50,000	378,500		May 12 04:07 PM
Patel Gautam	Director	May 05 '25	Sale	8.00	4,900	39,200	1,720,218	May 06 04:29 PM
Patel Gautam	Director	May 02 '25	Sale	8.00	3,768	30,144	1,725,118	May 06 04:29 PM
Gautam Patel	Director	May 02 '25	Proposed Sale	7.74	160,000	1,238,400		May 02 04:38 PM
Patel Gautam	Director	Apr 01 '25	Sale	8.30	80,000	664,000	1,728,886	Apr 02 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Amneal Pharmaceuticals Inc

Upgrade your FINVIZ experience